Menrik Biomerge Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.50 M
- Revenue Growth -15.14%
- Profit Growth -195.41%
- Ebitda -248.76%
- Net Worth -9.56%
- Total Assets -4.58%
About Menrik Biomerge
Menrik Biomerge Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 May 2017 (Seven years and nine months 1 days old ). Its registered office is in Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹9.50 M.
Vibhor Rastogi and Ketan Bansal serve as directors at the Company.
Company Details
- Location
Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24304DL2017PTC317030
- Company No.
317030
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Menrik Biomerge?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vibhor Rastogi  | Director | 01-May-2017 | Current |
| Ketan Bansal | Director | 01-May-2017 | Current |
Financial Performance of Menrik Biomerge.
Menrik Biomerge Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.14% decrease. The company also saw a substantial fall in profitability, with a 195.41% decrease in profit. The company's net worth dipped by a decrease of 9.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Menrik Biomerge?
In 2023, Menrik Biomerge had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rivpra Formulation Private LimitedVibhor Rastogi is a mutual person
Vibhor Buildcon (India) Private LimitedVibhor Rastogi is a mutual person
Charges (Loans)
₹9.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2018 | Others | ₹9.50 M | Open |
How Many Employees Work at Menrik Biomerge?
Unlock and access historical data on people associated with Menrik Biomerge, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Menrik Biomerge, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Menrik Biomerge's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.